Search Details

Word: swansons (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...went public. Genentech was founded by Robert Swanson, another former partner, sand Biologist Herbert Boyer. Today, Swanson is the president of Genentech, while Perkins is the chairman. The initial $200,000 put into the firm has swelled into stock worth $40 million...

Author: /time Magazine | Title: Boom Time in Venture Capital | 8/10/1981 | See Source »

Boyer's success is a result of brains and foresight, plus a strong independent streak. In 1976, after the first flush of public excitement about gene splicing, Boyer got an unexpected telephone call from Robert Swanson, a young venture capitalist. Swanson wanted to discuss the commercial possibilities of the new science, and many scientists might have kept him at arm's length. Boyer invited Swanson to his lab for a chat but told him he could only spare 20 minutes. The two hit it off so well they went on talking over beers at a local...

Author: /time Magazine | Title: Science: Blue-Chips for a Biochemist | 3/9/1981 | See Source »

Yielding to Swanson's enthusiasm, Boyer borrowed $500 and joined him in forming a company to exploit the new technology. They dubbed it Genentech (for genetic-engineering technology). As Boyer explains, "He wasn't happy with Boyer & Swanson, and I wasn't happy with Swanson & Boyer." The motives of the two were different. Swanson was 28, with degrees in chemistry and business administration from M.I.T. After several years of seeking out investment opportunities for others, he wanted to show the world he could succeed with a business of his own. Boyer, on the other hand, was interested...

Author: /time Magazine | Title: Science: Blue-Chips for a Biochemist | 3/9/1981 | See Source »

...extremely well. Today, after less than five years, Genentech probably has the best research facilities in the gene-splicing business (40 Ph.D.s, 65 technicians). It has produced and is testing half a dozen recombinant DNA products, including insulin, human growth hormone and various types of human interferon. Swanson gives Boyer the highest grades: "For an academic, he's got an incredible sense of what's important from a business standpoint...

Author: /time Magazine | Title: Science: Blue-Chips for a Biochemist | 3/9/1981 | See Source »

Boyer now draws only a consultant's fee for his Genentech work, but he has not exactly gone unrewarded. Like Swanson, he owns 925,000 shares of Genentech stock. Last October, when the stock shot up to $89 a share, he was briefly worth more than $80 million. Currently, with the stock at around $43, the figure is down to a mere $40 million or so. Watching the ebb and flow of this paper fortune, Boyer admits: "It's all a little unreal...

Author: /time Magazine | Title: Science: Blue-Chips for a Biochemist | 3/9/1981 | See Source »

Previous | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | Next